Search Results for "Ranbaxy Launches Atorvastatin In Us"

14:20 EDT 23rd September 2014 | BioPortfolio

Matching Channels


Lipitor was the best selling drug in 2009, with the 2009 annual sales coming in at over $5m for its company, Pfizer Inc. Lipitor is the brand name for an atorvastatin calcium medication that is pres...

Matching News

U.S. Pay-To-Delay Suit Against Ranbaxy, Pfizer Rejected

A U.S. judge threw out a suit filed against Ranbaxy Laboratories and Pfizer alleging they colluded to delay the market introduction of a generic of the top-selling Lipitor (atorvastatin) for high chol...

Dr Reddy’s launches generic amlodipine/atorvastatin

Indian generics giant Dr Reddy’s announced on 27 March 2014 the launch of its generic amlodipine/atorvastatin tablets in the US.

Sun Looks to Phase Out Ranbaxy in US

Sun Pharmaceutical Industries plans to purchase Ranbaxy Lboratories from Daiichi Sankyo Ltd for $3.2 B in stock plus taking on $800 M in Ranbaxy debt as announced yesterday. The combined Sun and Ranba...

Update-Moody's: Daiichi Sankyo Will Benefit from Sun Pharma's Acquisition of Ranbaxy

Sun Pharmaceutical Industries Ltd (Sun Pharma) & Ranbaxy Laboratories Ltd (Ranbaxy)

Under fire Ranbaxy sold to Sun Pharma for $4 billion

Sun Pharmaceutical Industries has bought struggling drugmaker Ranbaxy Laboratories in a deal that will see the two companies become one of the biggest in their native India. Sun has agreed to acquire ...

Sun Pharma and Ranbaxy engage in M&A transaction

Sun Pharmaceutical agreed to m&a transaction to buy competitor Ranbaxy Laboratories for $3.2 billion from Japan’s Daiichi Sankyo, which paid 61 percent more for the company five years ago. Ranba...

Sun Pharma Set For Bumpy Drive To Reach Ranbaxy

Analysts are growing cautious on the mega Sun-Ranbaxy deal, raising doubts on the timelines for regulatory approvals and the fallout of court proceedings. Some have questioned if an open bidding proce...

Cipher Pharmaceuticals signs distribution agreement with Ranbaxy

MISSISSAUGA, ON- Cipher Pharmaceuticals Inc. announces it has entered into a distribution and supply agreement with Ranbaxy Laboratories Ltd., granting Ranbaxy exclusive rights to market, sell and dis...

Matching PubMed Articles

Impact of switching treatment from rosuvastatin to atorvastatin on rates of cardiovascular events.

Now that generic atorvastatin has become available, a process of switching from rosuvastatin to atorvastatin may occur and could persist until the patent on branded rosuvastatin expires. It is importa...

Formulation and evaluation of fixed-dose combination of bilayer gastroretentive matrix tablet containing atorvastatin as fast-release and atenolol as sustained-release.

The objective of the present study was to develop bilayer tablets of atorvastatin and atenolol that are characterized by initial fast-release of atorvastatin in the stomach and comply with the release...

Efficacy and Safety of Alternate Day Therapy With Atorvastatin and Fenofibrate Combination in Mixed Dyslipidemia: A Randomized Controlled Trial.

Introduction:The long half-life of atorvastatin and fenofibrate makes them suitable for alternate day therapy. Hence, we aimed to study the efficacy, safety, and cost-effectiveness of alternate day th...

Comparison of low-dose rosuvastatin with atorvastatin in lipid-lowering efficacy and safety in a high-risk pakistani cohort: an open-label randomized trial.

Background. Treatment of hyperlipidemia is helpful in both primary and secondary prevention of coronary heart disease and stroke. Aim. To compare lipid-lowering efficacy of rosuvastatin with atorvasta...

Limitations of real-world treatment with atorvastatin monotherapy for lowering LDL-C in high-risk cardiovascular patients in the US.

Guidelines endorse statin therapy for lowering low-density lipoprotein cholesterol (LDL-C) to recommended levels, in patients with cardiovascular disease (CVD) risk, if needed, after lifestyle changes...

Search Whole site using Google

Search BioPortfolio:
Advertisement Advertisement